ATIPAMEZOLE HYDROCH

Atipamezole Hydrochloride Injection, Veterinary, is a 5 mg/mL intramuscular solution in 10 mL multi-dose vials, specifically for use in dogs to reverse the effects of medetomidine hydrochloride. The item is identified by NSN 6509-01-493-3405 and is procured under solicitation SPE2DP-26-T-3494, with a requirement for three vials at a fixed quantity with no variance allowed. Delivery is mandated within 20 days to Fort Bragg, North Carolina, under FOB destination terms, with inspection and acceptance also occurring at the destination. The product is regulated by the FDA, and contractors must submit a referral through EBS including manufacturer and bidder details for confirmation. Packaging must comply with MIL-STD-2073-1E and the latest Medical Marking Standard No. 1 from DLA, with all items marked in accordance with DLA requirements. A shelf life of 36 months, non-extendable and classified as TYPE I CODE Q, applies, and storage must be maintained at controlled room temperature. The item is subject to RD003 for covered defense information and RS020 for shelf-life compliance. The purchase unit is the vial (VI), and the contract aligns with DLA’s authorized unit of issue. Approved suppliers include Patterson Veterinary Supply, Covetrus North America, and Zoetis Inc., each with designated part numbers. All technical and quality requirements are governed by the DLA Master List of Technical and Quality Requirements, with therevision in effect on the solicitation issue date controlling for this simplified acquisition.